CDEK
← All drugs Report issue

ertumaxomab

mAbexperimentalMulti-specific

Ertumaxomab is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. — Wikipedia

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2006 (NCT00351858)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • T-cell surface glycoprotein CD3 epsilon chainACTIVATOR

    CD3E activator

    Immunomodulator. Trifunctional bispecific monoclonal antibody (mAb) has the capacity to enhance immunological effector functions such as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Designed to induce the formation of tri-cell-complexes consisting of Her2-positive tumor cells, CD3+ T cells, and Fc¿-receptor positive accessory cells.

  • Receptor protein-tyrosine kinase erbB-2BINDING AGENT

    ERBB2 binding agent

    Immunomodulator. Trifunctional bispecific monoclonal antibody (mAb) has the capacity to enhance immunological effector functions such as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Designed to induce the formation of tri-cell-complexes consisting of Her2-positive tumor cells, CD3+ T cells, and Fc¿-receptor positive accessory cells.

  • T-cell surface glycoprotein CD3 epsilon chainCROSS-LINKING AGENT

    T-cell surface glycoprotein CD3 epsilon chain cross-linking agent

    Immunomodulator. Trifunctional bispecific monoclonal antibody (mAb) has the capacity to enhance immunological effector functions such as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Designed to induce the formation of tri-cell-complexes consisting of Her2-positive tumor cells, CD3+ T cells, and Fcγ-receptor positive accessory cells.

  • Receptor protein-tyrosine kinase erbB-2CROSS-LINKING AGENT

    Receptor protein-tyrosine kinase erbB-2 cross-linking agent

    Immunomodulator. Trifunctional bispecific monoclonal antibody (mAb) has the capacity to enhance immunological effector functions such as antibody dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Designed to induce the formation of tri-cell-complexes consisting of Her2-positive tumor cells, CD3+ T cells, and Fcγ-receptor positive accessory cells.

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
Yes

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ertumaxomab
  • ertumaxomab
  • rexomun

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01569412Phase 1/Phase 2 (Phase 2)Mar 1, 2012J. W. Goethe University
NCT00522457Phase 2Jan 1, 2008Dartmouth University, Fresenius, Neovii Biotech
NCT00452140Phase 2Mar 1, 2007Neovii Biotech, Universidad Autonoma de Barcelona
NCT00351858Phase 2Jul 1, 2006Neovii Biotech
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Neovii BiotechFor profit3312006
Dartmouth UniversityAcademic/Hospital1012008
FreseniusFor profit1012008
J. W. Goethe UniversityAcademic/Hospital1112012
Universidad Autonoma de BarcelonaAcademic/Hospital1012007
5 organizations
Page 1 / 1